摘要
采用随机单盲对照方法，观察比较血脂康与美百乐镇的调脂疗效。４４例高脂血症患者随机分为血脂康组和美百乐镇组各２２例，疗程１２周。结果显示：１２周末血脂康组和美百乐镇组比较，总胆固醇、低密度脂蛋白胆固醇、载脂蛋白Ｂ分别下降２６．５９％和１８．９２％、３３．３２％和２４．２４％、１８．４２％和８．８９％，各自与治疗前相比及同期两组间比较均存在显著差异（Ｐ＜０．０１～０．００１），血脂康组中高密度脂蛋白胆固醇升高１３．９％（Ｐ＜０．０１），提示血脂康是国产高效的新一代调脂药。
The study was conducted in 44 patients with essential hyperlipidemia.They were randomly and equally divided to receive Xuezhikang and Mevalotin(10 mg daily)for a period of 12 weeks.At the end of the study,the data in decreasing TC,LDL C,ApoB and in increasing HLD C suggested that Xuezhikang is superior to Mevalotin.
出处
《中国新药杂志》
CAS
CSCD
1997年第4期265-268,共4页
Chinese Journal of New Drugs
关键词
血脂康
美百乐镇
高脂血症
血脂
载脂蛋白
Xuezhikang
Mevalotin:Hyperlipidemia
Plasma lipids
Apolipoprotein
